Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

2.28
+0.10004.59%
Post-market: 2.27-0.0100-0.44%19:12 EDT
Volume:241.65K
Turnover:546.42K
Market Cap:63.67M
PE:-0.38
High:2.33
Open:2.22
Low:2.20
Close:2.18
52wk High:26.05
52wk Low:2.16
Shares:27.92M
Float Shares:22.81M
Volume Ratio:0.51
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0237
EPS(LYR):-4.8865
ROE:-146.87%
ROA:-73.30%
PB:2.71
PE(LYR):-0.47

Loading ...

Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria

TIPRANKS
·
Oct 28

Jasper Therapeutics Highlights Promising Briquilimab Data in Chronic Urticaria and Other Inflammatory Diseases in Latest Corporate Presentation

Reuters
·
Oct 14

Director Svetlana Lucas Reports Acquisition of Common Shares of Jasper Therapeutics Inc

Reuters
·
Sep 25

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

TIPRANKS
·
Sep 22

Jasper Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Sep 22

U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla

Reuters
·
Sep 22

Jasper Therapeutics Inc : Btig Cuts Target Price to $7 From $20

THOMSON REUTERS
·
Sep 22

BTIG Remains a Buy on Jasper Therapeutics (JSPR)

TIPRANKS
·
Sep 20

Jasper Therapeutics Announces $30 Million Public Offering

TIPRANKS
·
Sep 20

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

TIPRANKS
·
Sep 19

Jasper Therapeutics Plans Public Offering of Securities

MT Newswires Live
·
Sep 19

Jasper Therapeutics Shares Down 9.7% After the Bell; Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

THOMSON REUTERS
·
Sep 19

Jasper Therapeutics Inc - Proceeds to Advance Briquilimab Development and Corporate Purposes

THOMSON REUTERS
·
Sep 19

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

GlobeNewswire
·
Sep 19

Jasper Therapeutics Inc. Unveils Presentation on Briquilimab's Efficacy and Safety in Chronic Urticaria

Reuters
·
Sep 03

Health Rounds: Experimental Jasper drug helps stem cell transplant patients avoid toxic chemotherapy in tiny trial

Reuters
·
Aug 27

Jasper Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Aug 15

UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating

MT Newswires Live
·
Aug 15

Jasper Therapeutics Q2 EPS $(1.74) Misses $(1.40) Estimate

Benzinga
·
Aug 14

Jasper Therapeutics Reports Q2 2025 Net Loss of $26.7 Million and EPS Loss of $1.74

Reuters
·
Aug 14